Karyopharm Therapeutics (KPTI) closed at $0.05 on November 6, 2026, down 8.5% from the previous close, on volume of 16,220,496 shares (30-day average 7,498,432).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 30, 2026 | Call Spread | 19-Jan-290.5 : 2.5 C | 200 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Karyopharm Therapeutics Announces Nasdaq Delisting Following Bankruptcy Filing
TipRanks (Thu, 5-Nov 8:11 AM ET)
Market Chameleon (Wed, 4-Nov 6:08 AM ET)
PRNewswire (Wed, 4-Nov 9:01 AM ET)
Karyopharm Therapeutics Files for Chapter 11 Bankruptcy Protection
TipRanks (Tue, 3-Nov 6:28 AM ET)
Karyopharm Announces Restructuring Agreement and Chapter 11 Filing
TipRanks (Mon, 2-Nov 10:00 AM ET)
Karyopharm files bankruptcy, to merge with Ayrmid
Seeking Alpha News (Mon, 2-Nov 8:13 AM ET)
PRNewswire (Mon, 2-Nov 7:11 AM ET)
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Thu, 1-Oct 4:05 PM ET)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Tue, 1-Sep 4:06 PM ET)
PRNewswire (Mon, 31-Aug 7:30 AM ET)
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Karyopharm Therapeutics trades on the NASDAQ stock market under the symbol KPTI.
As of November 6, 2026, KPTI stock price declined to $0.05 with 16,220,496 million shares trading.
KPTI has a beta of 6.69, meaning it tends to be more sensitive to market movements. KPTI has a correlation of 0.07 to the broad based SPY ETF.
KPTI has a market cap of $1.24 million. This is considered a Sub-Micro Cap stock.
Last quarter Karyopharm Therapeutics reported $33 million in Revenue and -$2.32 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.90.
In the last 3 years, KPTI traded as high as $29.25 and as low as $.04.
The top ETF exchange traded funds that KPTI belongs to (by Net Assets): VTI, VXF, VTWO, VTWV, VTWG.
KPTI has underperformed the market in the last year with a price return of -98.9% while the SPY ETF gained +10.8%. KPTI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -97.2% and -89.4%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
KPTI support price is $.05 and resistance is $.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KPTI shares will trade within this expected range on the day.
